Ionetix
Lansing, US · Delaware corporation
IONETIX manufactures radiopharmaceuticals and operates a network of compact superconducting cyclotrons for PET imaging and cancer therapy production. The company produces N-13 Ammonia tracers for cardiac imaging and targeted alpha therapy radiopharmaceuticals for oncology applications.
Founders & leadership
AS
Anthony StagnoliainExecutive
DE
David EveinExecutive
PP
Phun PhieuExecutive
KC
Kevin CameronExecutive
CB
CARRIE BUSCHinExecutive
Board
DM
David MartinBoard director
GT
Gregory TaxinBoard director
DB
Douglas BootheBoard director
MT
Michael TarnokBoard director
GM
Gregory MartinBoard director
MT
MICHAEL TARNOCKBoard director
Reported raises · per SEC filings
Form D private placements$61.1M disclosed across 2 of 4 rounds · 2016–2026
▶$15.4MofferedAug 2024 · PharmaceuticalsRule 506(b)
▶$15.4MofferedAug 2024 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David MartinDirector
- Anthony StagnoliaExecutive Officer
- David EveExecutive Officer
- Douglas BootheDirector
- Gregory TaxinDirector
- Phun PhieuExecutive Officer
- Michael TarnokDirector
- Gregory MartinDirector
- Kevin CameronExecutive Officer, Director
- Offering amount
- $15.4M
- Sales commissions
- $8.7M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.3MraisedMay 2020 · 24 investors · PharmaceuticalsRule 506(b)
▶$37.3MraisedMay 2020 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael TarnockDirector
- Gregory MartinDirector
- David MartinDirector
- Gregory TaxinDirector
- Nancy HargreavesExecutive Officer
- Kevin CameronExecutive Officer, Director
- Offering amount
- $43M
- Amount sold
- $37.3M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.8MraisedMar 2018 · 46 investors · PharmaceuticalsRule 506(b)
▶$23.8MraisedMar 2018 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- GREGORY TAXINDirector
- KEVIN J. CAMERONExecutive Officer, Director
- CARRIE BUSCHExecutive Officer
- MICHAEL TARNOCKDirector
- GREGORY MARTINDirector
- DAVID MARTINDirector
- Offering amount
- $25.4M
- Amount sold
- $23.8M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Ionetix do?
- IONETIX manufactures radiopharmaceuticals and operates a network of compact superconducting cyclotrons for PET imaging and cancer therapy production. The company produces N-13 Ammonia tracers for cardiac imaging and targeted alpha therapy radiopharmaceuticals for oncology applications.
- How much funding has Ionetix raised?
- Ionetix has disclosed $61.1M raised across 2 of its 4 known rounds.
- Where is Ionetix headquartered?
- Ionetix is headquartered in Lansing, US.